More on RO
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.94 |
|
|||
| Open | $7.94 | ||||
| 52 Wk High | $8.59 | ||||
| 52 Wk Low | $7.82 | ||||
| Day High | $8.59 | ||||
| Day Low | $7.82 | ||||
| P/E | 6.53 | ||||
| EPS | $1.30 | ||||
| Volume | 42,732 | ||||
- New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
- Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
- Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions
- FDA approves Genentech's Venclexta plus acalabrutinib for CLL treatment
- FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
- FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
- Flatiron Launches First-of-Its-Kind AI-Powered Global Prostate Cancer Datasets
- Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
Entities mentioned with RO
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Industrial Production | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- AdCom | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
